Transcend Therapeutics Announces Primary Endpoint Met in IMPACT-1 Phase 2 Study of TSND-201 in PTSD

Transcend Therapeutics Announces Primary Endpoint Met in IMPACT-1 Phase 2 Study of TSND-201 in PTSD

Primary endpoint met, with TSND-201 demonstrating statistically significant placebo-adjusted CAPS-5 improvement of -9.64 points on Day 64 (p = 0.011)TSND-201 demonstrated rapid improvements, with a statistically significant placebo-adjusted CAPS-5 improvement of -8.00 points on Day 10 (p = 0.012), with…

Transcend Posts Positive Phase 2 Data from Methylone for PTSD Program - Psychedelic Alpha

Words by Josh Hardman with support from Psychedelic Alpha Medical Advisor Michael Haichin. *** Today, Transcend Therapeutics shared topline results from its Phase 2 study of the MDMA analog methylone (TSND-201) in PTSD. The trial, IMPACT-1 (NCT05741710), enrolled 65 severe PTSD patients to receive either methylone or placebo capsules once weekly for four weeks… Source

Transcend’s PTSD therapy shows potential in Phase II trial

The company’s Phase II IMPACT-1 trial found treatment with TSND-201 was generally safe and well tolerated in PTSD patients.The post Transcend’s PTSD therapy shows potential in Phase II trial appeared first on Clinical Trials Arena.

Exclusive: Transcend notches Phase 2 win to treat PTSD, invigorating budding neuroplastogen class

Transcend Therapeutics’ PTSD treatment succeeded in a mid-stage study, propelling the scrappy company of less than 20 people toward a Phase 3 trial that could begin at the start of next year. The placebo-controlled results ...